

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1600RXA

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	JAN 27	Source of Registration (SR) information in REGISTRY updated and searchable
NEWS	4	JAN 27	A new search aid, the Company Name Thesaurus, available in CA/CAPLUS
NEWS	5	FEB 05	German (DE) application and patent publication number format changes
NEWS	6	MAR 03	MEDLINE and LMEADLINE reloaded
NEWS	7	MAR 03	MEDLINE file segment of TOXCENTER reloaded
NEWS	8	MAR 03	FRANCEPAT now available on STN
NEWS	9	MAR 29	Pharmaceutical Substances (PS) now available on STN
NEWS	10	MAR 29	WPIFV now available on STN
NEWS	11	MAR 29	New monthly current-awareness alert (SDI) frequency in RAPRA
NEWS	12	APR 26	PROMT: New display field available
NEWS	13	APR 26	IFIPAT/IFIUDB/IFICDB: New super search and display field available
NEWS	14	APR 26	LITALERT now available on STN
NEWS	15	APR 27	NLDB: New search and display fields available
NEWS	16	May 10	PROUSDDR now available on STN
NEWS	17	May 19	PROUSDDR: One FREE connect hour, per account, in both May and June 2004
NEWS	18	May 12	EXTEND option available in structure searching
NEWS	19	May 12	Polymer links for the POLYLINK command completed in REGISTRY
NEWS	20	May 17	FRFULL now available on STN
NEWS EXPRESS			MARCH 31 CURRENT WINDOWS VERSION IS V7.00A, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 26 APRIL 2004
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS INTER			General Internet Information
NEWS LOGIN			Welcome Banner and News Items
NEWS PHONE			Direct Dial and Telecommunication Network Access to STN
NEWS WWW			CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 08:29:27 ON 22 MAY 2004

=> fil reg

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.21	0.21

FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 08:29:51 ON 22 MAY 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 20 MAY 2004 HIGHEST RN 684211-73-2

DICTIONARY FILE UPDATES: 20 MAY 2004 HIGHEST RN 684211-73-2

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004


Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=>

Uploading C:\STNEXP4\QUERIES\10629992.str



chain nodes :

10 11 12 13 14 16 17

ring nodes :

1 2 3 4 5 6 7 8 9

chain bonds :

7-10 9-16 10-11 11-12 11-13 16-17

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9

exact/norm bonds :

5-7 6-9 7-8 8-9 9-16 11-12 11-13

exact bonds :

7-10 10-11 16-17

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:Atom

L1 STRUCTURE UPLOADED

=> d

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 08:30:07 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 457 TO ITERATE

100.0% PROCESSED 457 ITERATIONS
SEARCH TIME: 00.00.01

46 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 7858 TO 10422
PROJECTED ANSWERS: 514 TO 1326

L2 46 SEA SSS SAM L1

=> s l1 full

FULL SEARCH INITIATED 08:30:10 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 8961 TO ITERATE


100.0% PROCESSED 8961 ITERATIONS
SEARCH TIME: 00.00.01

1067 ANSWERS

L3 1067 SEA SSS FUL L1

=>

Uploading C:\STNEXP4\QUERIES\10629992b.str



chain nodes :

10 11 12 13 14 16 17 20 21 22 23

ring nodes :

1 2 3 4 5 6 7 8 9

chain bonds :

7-10 9-16 10-11 11-12 11-13 14-20 16-17 20-21 21-22 21-23

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9

exact/norm bonds :

5-7 6-9 7-8 8-9 9-16 11-12 11-13 14-20 21-22 21-23

exact bonds :

7-10 10-11 16-17 20-21

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS

11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:Atom 20:CLASS


21:CLASS 22:CLASS 23:CLASS

L4 STRUCTURE UPLOADED

=> d

L4 HAS NO ANSWERS

L4 STR



Structure attributes must be viewed using STN Express query preparation.

=> s 14 subset=l3 full

FULL SUBSET SEARCH INITIATED 08:31:23 FILE 'REGISTRY'

FULL SUBSET SCREEN SEARCH COMPLETED - 93 TO ITERATE

100.0% PROCESSED 93 ITERATIONS

62 ANSWERS

SEARCH TIME: 00.00.01

L5 62 SEA SUB=L3 SSS FUL L4

=> s 15 and caplus/lc

35440044 CAPLUS/LC

L6 62 L5 AND CAPLUS/LC

=> fil caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

197.34

197.55

FILE 'CAPLUS' ENTERED AT 08:31:32 ON 22 MAY 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 22 May 2004 VOL 140 ISS 22
FILE LAST UPDATED: 21 May 2004 (20040521/ED)

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> s 16


L7 16 L6

=> d ibib abs hitstr 1-16

L7 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2002:736140 CAPLUS
 DOCUMENT NUMBER: 137:242179
 TITLE: Remedies for arteriosclerosis
 INVENTOR(S): Saiga, Akihiko; Ono, Takashi; Yamada, Katsutoshi;
 Hanasaki, Kohji
 PATENT ASSIGNEE(S): Shionogi & Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 83 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002074342	A1	20020926	WO 2002-JP2585	20020319
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, EF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
EP 1378246	A1	20040107	EP 2002-705327	20020319
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
ER 2002008275	A	20040413	BR 2002-8275	20020319
PRIORITY APPLN. INFO.:			JP 2001-78569	A 20010319
			JP 2001-401269	A 20011228
			WO 2002-JP2585	W 20020319

OTHER SOURCE(S): MARPAT 137:242179
 AB Novel remedies and preventives for arteriosclerosis which are characterized by treating or preventing arteriosclerosis with the use of V type and/or X type sPLA2 inhibitors.
 IT 258262-60-9
 RI: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (remedies for arteriosclerosis)
 RN 258262-60-9 CAPLUS
 CN 1H-Indole-3-acetamide, 2-ethyl- α -oxo-4-[2-oxo-2-(phenylsulfonyl)amino]ethoxy]-1-(phenylmethyl)- (9CI) (CA INDEX NAME)




L7 ANSWER 2 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2002:487526 CAPLUS
 DOCUMENT NUMBER: 137:47112
 TITLE: Novel sPLA2 inhibitors
 INVENTOR(S): Beight, Douglas Wade; Kinnick, Michael Dean; Lin, Ho-Shan; Morin, John Michael, Jr.; Richatt, Michael Enrique; Sall, Daniel Jon; Sawyer, Jason Scott; Smith, Edward C. R.
 PATENT ASSIGNEE(S): Eli Lilly and Company, USA
 SOURCE: PCT Int. Appl., 174 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002050030	A2	20020627	WO 2001-US43187	20011206
WO 2002050030	C1	20031113		
WO 2002050030	A3	20020912		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, FR, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, ME, MG, MK, MN, MW, MX, MY, NZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2002033928	A5	20020701	AU 2002-33928	20011206
EP 1349834	A2	20031008	EP 2001-984924	20011206
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
US 2004077704	A1	20040422	US 2003-450741	20030616
PRIORITY APPLN. INFO.:			US 2000-256397P	P 20001218
			WO 2001-US43187	W 20011206

OTHER SOURCE(S): MARPAT 137:47112
 AB A novel class of cycloalkyl fused indole compds. is disclosed together with such compds. for inhibiting sPLA2 mediated release of fatty acids for treatment of inflammatory Diseases such as septic shock. Approx. 20 cyclopent- and cyclohexylindoles were prepared in several steps by standard methods and were tested as inhibitors of sPLA2. E.g., 2-[4-(2-benzenesulfonylamino-2-oxoethoxy)-1-benzyl-2-methyl-1,6,7,8-tetrahydro-1-aza-as-indacen-3-yl]-2-oxoacetamide, 2-[[3-(2-amino-1,2-dioxoethyl)-2-methyl-1-(2-fluorobenzyl)-1,6,7,8-tetrahydrocyclopent[9]indol-4-yl]oxy]acetic acid, and 2-[[3-(2-amino-1,2-dioxoethyl)-1-benzyl-2-methyl-6,7,8,9-tetrahydro-1H-benz[9]indol-4-yl]oxy]acetic acid exhibited IC50 values of 0.007, 0.009 and 0.010 μ M, resp.
 IT 438623-60-0P
 RI: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation) (preparation of cycloalkyl fused indoles as sPLA2 inhibitors)
 RN 438623-60-0 CAPLUS
 CN Cyclopent[9]indole-3-acetamide, 1,6,7,8-tetrahydro-2-methyl- α -oxo-4-[2-oxo-2-(phenylsulfonyl)amino]ethoxy]-1-(phenylmethyl)- (9CI) (CA INDEX NAME)

L7 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L7 ANSWER 2 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



L7 ANSWER 3 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2002:487524 CAPLUS
 DOCUMENT NUMBER: 137:47110
 TITLE: Novel sPLA2 inhibitors
 INVENTOR(S): Beight, Douglas Wade; Kinnick, Michael Deans; Lin, Ho-Shen; Morin, John Michael, Jr.; Richett, Michael Enrico; Sall, Daniel Jon; Sawyer, Jason Scott; Smith, Edward C. R.
 PATENT ASSIGNEE(S): Eli Lilly and Company, USA
 SOURCE: PCT Int. Appl., 97 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002050028	A2	20020627	WO 2001-0543184	20011206
WO 2002050028	A3	20020919		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, FR, GB, GD, GE, GR, GU, HK, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, FF, RU, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
AU 2002037655	A5	20020701	AU 2002-37655	20011206
EP 1349832	A2	20031008	EP 2001-986459	20011206
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
US 2004059130	A1	20040325	US 2003-450929	20030616
PRIORITY APPLN. INFO.:			US 2000-256281P	P 20001218
			WO 2001-US43184	W 20011206

OTHER SOURCE(S): MARPAT 137:47110
 GI




AB A novel class of benz[f]indole compds. is disclosed together using such compds. for inhibiting sPLA2 mediated release of fatty acids for treatment of inflammatory Diseases such as septic shock. Thus, benzindole I, prepared

L7 ANSWER 4 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2002:10441 CAPLUS
 DOCUMENT NUMBER: 136:69735
 TITLE: Preparation of heterocyclic compounds as X-type sPLA2 inhibitors
 INVENTOR(S): Ogiwara, Tomoyuki; Sano, Kaoru; Hanasaki, Kohji; Ikeda, Minoru; Ono, Takashi
 PATENT ASSIGNEE(S): Shionogi & Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 87 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002090621	A1	20020103	WO 2001-JP5479	20010627
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, FR, GB, GD, GE, GR, GU, HK, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, FF, RU, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
AU 2001067823	A5	20020108	AU 2001-67823	20010627
US 2003181454	A1	20030925	US 2002-311282	20021217
PRIORITY APPLN. INFO.:			JP 2000-195430	A 20000629
			WO 2001-JP5479	W 20010627

OTHER SOURCE(S): MARPAT 136:69735
 GI




AB The title compds., e.g. I [R20 is OCH2COOH or the like; R21 is COCONH2 or the like; R22 is C1-6 alkyl; R23 is CH2R18 (wherein R18 is aryl or the like); and R24 is hydrogen or C1-6 alkyl], are prepared. The title compound


L7 ANSWER 3 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 in several steps by std. methods, exhibited an inhibition value IC50 of 1.06 μM against sPLA2.
 IT 438587-51-OP
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of benzindoles as sPLA2 inhibitors)
 RN 438587-51-0 CAPLUS
 CN 1H-Benz[1]indole-3-acetamide, 2-methyl-α-oxo-4-[2-oxo-2-[(phenylsulfonyl)amino]ethoxy]-1-(phenylmethyl)- (9CI) (CA INDEX NAME)




L7 ANSWER 4 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 in vitro showed IC50 of 0.008 μM against X-type sPLA2. Formulations are given.
 IT 383860-24-OP 383860-30-8P 383860-31-9P 383860-32-OP 383860-33-1P 383860-34-2P 383860-35-3P 383860-36-4P 383860-37-5P 383860-38-6P 383860-40-OP 383860-41-1P 383860-44-4P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of heterocyclic compds. as X-type sPLA2 inhibitors)
 RN 383860-24-0 CAPLUS
 CN 1H-Indole-3-acetamide, 6-methyl-2-(2-methylpropyl)-α-oxo-4-[2-oxo-2-[(phenylsulfonyl)amino]ethoxy]-1-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 383860-30-8 CAPLUS
 CN 1H-Indole-3-acetamide, 2-(2-methylpropyl)-α-oxo-4-[2-oxo-2-[(phenylsulfonyl)amino]ethoxy]-1-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 383860-31-9 CAPLUS
 CN 1H-Indole-3-acetamide, 1-[(4-fluorophenyl)methyl]-2-(2-methylpropyl)-α-oxo-4-[2-oxo-2-[(phenylsulfonyl)amino]ethoxy]-1-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 383860-32-0 CAPLUS


L7 ANSWER 4 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 CN 1H-Indole-3-acetamide, 2-(2-methylpropyl)-4-[2-[(methylsulfonyl)amino]-2-oxoethoxy]- α -oxo-1-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 383860-33-1 CAPLUS
 CN 1H-Indole-3-acetamide, 6-methyl-2-(2-methylpropyl)-4-[2-[(methylsulfonyl)amino]-2-oxoethoxy]- α -oxo-1-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 383860-34-2 CAPLUS
 CN 1H-Indole-3-acetamide, 4-[2-[(ethylsulfonyl)amino]-2-oxoethoxy]-2-(2-methylpropyl)- α -oxo-1-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 383860-35-3 CAPLUS
 CN 1H-Indole-3-acetamide, 2-(2-methylpropyl)- α -oxo-4-[2-oxo-2-[(propylsulfonyl)amino]ethoxy]-1-(phenylmethyl)- (9CI) (CA INDEX NAME)


L7 ANSWER 4 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 383860-40-0 CAPLUS
 CN 1H-Indole-3-acetamide, 2-(2-methylpropyl)-4-[2-[(methylsulfonyl)amino]-2-oxoethoxy]-1-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 383860-41-1 CAPLUS
 CN 1H-Indole-3-acetamide, 4-[2-[[1-methylethylsulfonyl]amino]-2-oxoethoxy]-2-(2-methylpropyl)-1-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 383860-44-4 CAPLUS
 CN 1H-Indole-3-acetamide, 4-[2-(cyanamino)-2-oxoethoxy]-6-methyl-2-(2-methylpropyl)- α -oxo-1-(phenylmethyl)- (9CI) (CA INDEX NAME)


L7 ANSWER 4 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 383860-36-4 CAPLUS
 CN 1H-Indole-3-acetamide, 4-[2-[[1-methylethylsulfonyl]amino]-2-oxoethoxy]-2-(2-methylpropyl)- α -oxo-1-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 383860-37-5 CAPLUS
 CN 1H-Indole-3-acetamide, 4-[2-[(butylsulfonyl)amino]-2-oxoethoxy]-2-(2-methylpropyl)- α -oxo-1-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 383860-38-6 CAPLUS
 CN 1H-Indole-3-acetamide, 2-(2-methylpropyl)- α -oxo-4-[2-oxo-2-[[trifluoromethylsulfonyl]amino]ethoxy]-1-(phenylmethyl)- (9CI) (CA INDEX NAME)

L7 ANSWER 4 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



IT 383860-72-89
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of heterocyclic compds. as X-type sPLA2 inhibitors)

RN 383860-72-8 CAPLUS
 CN 1H-Indole-3-acetamide, α -hydroxy-2-(2-methylpropyl)-4-[2-[(methylsulfonyl)amino]-2-oxoethoxy]-1-(phenylmethyl)- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 5 OF 16 CAPLUS COPYRIGHT 2004 ACS ON STN
 ACCESSION NUMBER: 2002:10308 CAPLUS
 DOCUMENT NUMBER: 136:64151
 TITLE: Secretory PLA2 inhibitors as remedies for Alzheimer's disease
 INVENTOR(S): Hanasaki, Kohji; Ikeda, Minoru; Ono, Takashi
 PATENT ASSIGNEE(S): Shionogi & Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 45 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002000257	A1	20020103	WO 2001-JP5482	20010627
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BE, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.: JP 2000-195445 A 20000629
 OTHER SOURCE(S): MARPAT 136:64151

AB It is found out that type X sPLA2 inhibitors are useful in preventing or treating Alzheimer's disease.
 IT 258262-50-9
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (secretory PLA2 inhibitors as remedies for Alzheimer's disease)
 RN 258262-50-9 CAPLUS
 CN 1H-Indole-3-acetamide, 2-ethyl- α -oxo-4-[2-oxo-2-[(phenylsulfonyl)amino]ethoxy]-1-(phenylmethyl)- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 6 OF 16 CAPLUS COPYRIGHT 2004 ACS ON STN
 ACCESSION NUMBER: 2002:10307 CAPLUS
 DOCUMENT NUMBER: 136:64164
 TITLE: Remedies for cirrhosis
 INVENTOR(S): Hanasaki, Kohji; Ikeda, Minoru; Ono, Takashi
 PATENT ASSIGNEE(S): Shionogi & Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 45 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002000256	A1	20020103	WO 2001-JP5481	20010627
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BE, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.: JP 2000-195436 A 20000629
 OTHER SOURCE(S): MARPAT 136:64164

AB It is found out that type X sPLA2 inhibitors are useful in preventing or treating cirrhosis.
 IT 258262-50-9
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (secretory PLA2 inhibitors as remedies for cirrhosis)
 RN 258262-50-9 CAPLUS
 CN 1H-Indole-3-acetamide, 2-ethyl- α -oxo-4-[2-oxo-2-[(phenylsulfonyl)amino]ethoxy]-1-(phenylmethyl)- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2004 ACS ON STN
 ACCESSION NUMBER: 2002:10306 CAPLUS
 DOCUMENT NUMBER: 136:64112
 TITLE: Remedies for cancer
 INVENTOR(S): Hanasaki, Kohji; Ikeda, Minoru; Ono, Takashi
 PATENT ASSIGNEE(S): Shionogi & Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 56 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002000255	A1	20020103	WO 2001-JP5480	20010627
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BE, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
AU 2001067824	A5	20020108	AU 2001-67824	20010627
EP 1300159	A1	20030409	EP 2001-945613	20010627
US 2004077651	A1	20040422	US 2002-312451	20021227

PRIORITY APPLN. INFO.: JP 2000-195434 A 20000629
 WO 2001-JP5480 W 20010627

OTHER SOURCE(S): MARPAT 136:64112
 AB It is found out that type X secretory PLA2 inhibitors are useful in preventing or treating cancer.
 IT 258262-50-9
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (type X secretory PLA2 inhibitors as remedies for cancer)
 RN 258262-50-9 CAPLUS
 CN 1H-Indole-3-acetamide, 2-ethyl- α -oxo-4-[2-oxo-2-[(phenylsulfonyl)amino]ethoxy]-1-(phenylmethyl)- (9CI) (CA INDEX NAME)





REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 8 OF 16 CAPLUS COPYRIGHT 2004 ACS ON STN
 ACCESSION NUMBER: 2001:283786 CAPLUS
 DOCUMENT NUMBER: 134:290409
 TITLE: Preparation of V type and/or X type sPLA2 inhibitors
 INVENTOR(S): Ono, Takashi; Ueno, Masahiko; Hanasaki, Kohji
 PATENT ASSIGNEE(S): Shionogi & Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 58 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001026653	A1	20010419	WO 2000-JP7024	20001010
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BE, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.: JP 1999-293273 A 19991015
 OTHER SOURCE(S): MARPAT 134:290409

G1




AB V type and/or X type sPLA2 inhibitors which contain as the active ingredient compds. represented by general formulas [I: X = CHR2, N1 = C, N2 = C, N3 = R6; Z = R7; Y2 = C(CONH2)CHCH:CH; R1 = CH, NH5O2C6H5; R2, R3, R4 independently = H, CH3, C6H5, F; R5 =

L7 ANSWER 8 OF 16 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)
 4-C6H5C6H4CH2, C6H5CH2, cyclohexylmethyl, 2-nylupentylphenyl; R6 = H, C1-3 alkyl; R7 = COCONH2, CH2CONH2; dotted bond = single, double], prodrugs thereof, and pharmaceutically acceptable salts of the same or solvates of the same are prepd. as V type and/or X type sPLA2 inhibitors. Thus, the title compd. II was prepd. and tested for X type sPLA2 inhibition with an IC50 of 3 nM.

IT 258262-50-9P
 RL: FAC (Biological activity or effector, except adverse); ESU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation of V type and/or X type sPLA2 inhibitors)

RN 258262-50-9 CAPLUS

CN 1H-indole-3-acetamide, 2-ethyl-4-[2-oxo-2-[(phenylsulfonyl)amino]ethoxy]-1-(phenylmethyl)- (SCI) (CA INDEX NAME)




REFERENCE COUNT: 64 THERE ARE 64 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 9 OF 16 CAPLUS COPYRIGHT 2004 ACS ON STN
 ACCESSION NUMBER: 2001:228857 CAPLUS
 DOCUMENT NUMBER: 134:252258
 TITLE: Preparation of indole derivatives as human non-pancreatic secretory phospholipase A2 (sPLA2) inhibitors
 INVENTOR(S): Harper, Richard Walter; Lin, Mo-Shen; Richett, Michael Enriquez
 PATENT ASSIGNEE(S): Eli Lilly and Company, USA
 SOURCE: PCT Int. Appl., 117 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001021587	A2	20010329	WO 2000-US20816	20000907
WO 2001021587	A3	20011011		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DO, EE, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, BG, GR, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
EF 1220839	A2	20020710	EF 2000-859170	20000907
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, YT, IE, SI, LT, LV, FI, RO, MK, CY, AL			
JP 2003009491	T2	20030311	JP 2001-524967	20000907
US 2004029948	A1	20040212	US 2003-629992	20030730
PRIORITY APPL. INFO.:			US 1999-154836P	P 19990920
			WO 2000-US20816	W 20000907
			US 2002-69824	A3 20020221

OTHER SOURCE(S): MARPAT 134:252258
 GI




AB A class of novel indole represented by formula [I; R1 is selected from groups (a), (b), and (c) wherein: (a) is C7-20 alkyl, C7-20 haloalkyl, C7-20 alkenyl, C7-20 alkynyl, carbocyclic radical, or heterocyclic

L7 ANSWER 9 OF 16 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)
 radical, or (b) is a member of (a) substituted with one or more independently selected non-interfering substituents; or (c) is (a) or (b) group linked to a divalent linking group of 1 to 8 atoms; R2 is hydrogen, or a group contg. 1 to 4 nonhydrogen atoms plus any required hydrogen atoms; R3 is -(L3)-2, where (L3) is a divalent linker group selected from a bond or a divalent group selected from CH2, O, S, NH, CO and Z is selected from a group represented by the formulas, C(=NORa)C(=X)NH2, C(=X)CONH2, C(Ra)ZC(=X)NH2 or wherein, X is oxygen or sulfur; and Ra is selected from hydrogen, C1-8 alkyl, aryl, C1-8 alkaryl, C1-8 alkoxy, aralkyl and cyano; R4 is the group, -(Lh)- (hydroxyfunctional amide); wherein (Lh), is an hydroxyfunctional amide linker having an hydroxyfunctional amide linker length of 1 to 8; R5 is selected from hydrogen, a non-interfering substituent, or the group, -(La)-(acidic group); wherein -(La)-, is an acid linker having an acid linker length of 1 to 8; R6 and R7 are selected from hydrogen, non-interfering substituent, carbocyclic radical, carbocyclic radical substituted with non-interfering substituent(s), heterocyclic radicals, and heterocyclic radical substituted with non-interfering substituent(s)] is prepd. These compds. inhibit sPLA2-mediated release of fatty acids for treatment of inflammatory diseases such as septic shock. Thus, [[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetic acid Me ester was condensed with O-phenylhydroxylamine hydrochloride in the presence of collidine and benzotriazole-1-yl-oxytris(dimethylamino)phosphonium hexafluorophosphate in DMF at ambient temp. for 2 h to give 2-[[3-(aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-N-(phenyloxy)acetamide (II). II in vitro showed IC50 of 9.0±2.0 nM against sPLA2.

IT 331440-80-3P 331440-82-5P 331440-84-7P
 331440-86-9P 331440-88-1P 331440-90-5P
 331440-92-7P 331440-95-0P 331440-97-2P
 331440-99-4P 331441-01-1P 331441-03-3P
 331441-05-5P 331441-07-7P 331441-09-9P
 331441-15-7P
 RL: FAC (Biological activity or effector, except adverse); ESU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of indole derivs. as human non-pancreatic secretory phospholipase A2 (sPLA2) inhibitors and inhibitors of sPLA2-mediated release of fatty acids for treatment of inflammatory diseases such as septic shock)

RN 331440-80-3 CAPLUS


CN 1H-Indole-3-acetamide, 2-ethyl-4-[2-(hydroxyamino)-2-oxoethoxy]-α-oxo-1-(phenylmethyl)- (SCI) (CA INDEX NAME)



RN 331440-82-5 CAPLUS


CN 1H-Indole-3-acetamide, 2-ethyl-4-[2-(methoxyamino)-2-oxoethoxy]-α-oxo-1-(phenylmethyl)- (SCI) (CA INDEX NAME)

L7 ANSWER 9 OF 16 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)




RN 331440-84-7 CAPLUS

CN 1H-Indole-3-acetamide, 2-ethyl-4-[2-(methoxymethylamino)-2-oxoethoxy]-α-oxo-1-(phenylmethyl)- (SCI) (CA INDEX NAME)




RN 331440-86-9 CAPLUS

CN 1H-Indole-3-acetamide, 2-ethyl-4-[2-(hydroxymethylamino)-2-oxoethoxy]-α-oxo-1-(phenylmethyl)- (SCI) (CA INDEX NAME)




RN 331440-88-1 CAPLUS


CN 1H-Indole-3-acetamide, 4-[2-(ethoxyamino)-2-oxoethoxy]-2-ethyl-α-oxo-1-(phenylmethyl)- (SCI) (CA INDEX NAME)




L7 ANSWER 9 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 RN 331440-90-5 CAPLUS
 CN 1H-Indole-3-acetamide, 2-ethyl- α -oxo-4-[2-oxo-2-[(2-propenyl-oxo)amino]ethoxy]-1-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 331440-92-7 CAPLUS
 CN 1H-Indole-3-acetamide, 2-ethyl-4-[2-(hydroxy-2-propenylamino)-2-oxoethoxy]- α -oxo-1-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 331440-95-0 CAPLUS
 CN 1H-Indole-3-acetamide, 4-[2-[(1,1-dimethylethoxy)amino]-2-oxoethoxy]-2-ethyl- α -oxo-1-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 331440-97-2 CAPLUS
 CN 1H-Indole-3-acetamide, 2-ethyl-4-[2-[(2-methylpropoxy)amino]-2-oxoethoxy]- α -oxo-1-(phenylmethyl)- (9CI) (CA INDEX NAME)


L7 ANSWER 9 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 331441-05-5 CAPLUS
 CN 1H-Indole-3-acetamide, 2-ethyl-4-[2-(methylphenoxylamino)-2-oxoethoxy]- α -oxo-1-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 331441-07-7 CAPLUS
 CN 1H-Indole-3-acetamide, 4-[2-(cyclohexylhydroxyamino)-2-oxoethoxy]-2-ethyl- α -oxo-1-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 331441-09-9 CAPLUS
 CN 1H-Indole-3-acetamide, 2-ethyl-4-[2-(hydroxyamino)-2-oxoethoxy]-1-(phenylmethyl)- (9CI) (CA INDEX NAME)


L7 ANSWER 9 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 331440-99-4 CAPLUS
 CN 1H-Indole-3-acetamide, 2-ethyl- α -oxo-4-[2-oxo-2-[(phenylmethoxy)amino]ethoxy]-1-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 331441-01-1 CAPLUS
 CN 1H-Indole-3-acetamide, 2-ethyl-4-[2-[methyl(phenylmethoxy)amino]-2-oxoethoxy]- α -oxo-1-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 331441-03-3 CAPLUS
 CN 1H-Indole-3-acetamide, 2-ethyl- α -oxo-4-[2-oxo-2-(phenoxylamino)ethoxy]-1-(phenylmethyl)- (9CI) (CA INDEX NAME)

L7 ANSWER 9 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 331441-15-7 CAPLUS
 CN 1H-Indole-3-acetamide, 2-ethyl-4-[2-(hydroxy(phenylmethyl)amino)-2-oxoethoxy]- α -oxo-1-(phenylmethyl)- (9CI) (CA INDEX NAME)



L7 ANSWER 10 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2001:227212 CAPLUS

DOCUMENT NUMBER: 135140417

TITLE: A molecular modeling and 3D QSAR study of a large series of indole inhibitors of human non-pancreatic secretory phospholipase A2

AUTHOR(S): Bernard, Philippe; Pintore, Marco; Berthon, Jean-Yves; Chretien, Jacques R.

CORPORATE SOURCE: Laboratory of Chemometrics and Bioinformatics, University of Orleans, Orleans, 45067, Fr.

SOURCE: European Journal of Medicinal Chemistry (2001), 36(1), 1-19

PUBLISHER: Editions Scientifiques et Medicales Elsevier

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Automated docking allowing protein-based alignment was performed for a series of 188 indole inhibitors of the human non-pancreatic secretory phospholipase A2 (hnp-PLA2). All the substituted indoles were docked to the crystal structure of hnp-PLA2 and a three-dimensional QSAR model was then established using the CoMFA method. The set of 188 compds. was divided into two subsets, the first one constituting the training set (126 compds.), while the second constituted the test set (62 compds.). The established CoMFA model derived from the training set was then applied to the test set. A good correlation between predicted and exptl. activity data allows to validate the 3D QSAR model. A second and global 3D QSAR including all the compds. was established, allowing the creation of the hnp-PLA2 pharmacophore.

IT 164083-87-8 164083-88-9 185298-58-2


344741-31-7 344741-32-8

RI: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); FRP (Properties); BIOL (Biological study)

(a mol. modeling and 3D QSAR study of a large series of indole inhibitors of human non-pancreatic secretory phospholipase A2)

RN 164083-87-8 CAPLUS

CN Acetic acid, [(3-(2-amino-2-oxoethyl)-2-methyl-1-(phenylmethyl)-1H-indol-4-yl)oxy]-, hydrazide (9CI) (CA INDEX NAME)




RN 164083-88-9 CAPLUS

CN 1H-Indole-3-acetamide, 4-(2-amino-2-oxoethoxy)-2-methyl-1-(phenylmethyl)- (9CI) (CA INDEX NAME)

L7 ANSWER 10 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


REFERENCE COUNT: 57 THERE ARE 57 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 10 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 185298-58-2 CAPLUS

CN 1H-Indole-3-acetamide, 4-(2-amino-2-oxoethoxy)-2-ethyl-1-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 344741-31-7 CAPLUS

CN Acetic acid, [(3-(2-amino-2-oxoethyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl)oxy]-, hydrazide (9CI) (CA INDEX NAME)



RN 344741-32-8 CAPLUS

CN 1H-Indole-3-acetamide, 4-(2-amino-2-oxoethoxy)-2-ethyl-1-(phenylmethyl)- (9CI) (CA INDEX NAME)



L7 ANSWER 10 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

L7 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2001:63270 CAPLUS

DOCUMENT NUMBER: 134116236

TITLE: Preparation of indole amino acid derivatives as secretory phospholipase A2 (sPLA2) inhibitors

INVENTOR(S): Lin, Mo-Shen; Richett, Michael Enrico

PATENT ASSIGNEE(S): Eli Lilly and Company, USA

SOURCE: PCT Int. Appl., 142 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001005761	A1	20010125	WO 2000-US16319	20000711
<p>W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GR, HK, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM</p> <p>RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG</p>				
EP 1202963	A1	20020508	EP 2000-944673	20000711
<p>R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, HK, CY, AL</p>				
JP 2003505372	T2	20030212	JP 2001-511422	20000711
US 6706752	B1	20040316	US 2001-18037	20011211
US 2003153770	A1	20030814	US 2002-260450	20020927
US 6635670	B2	20031021		
PRIORITY APPLN. INFO.:				
			US 1999-144502P	P 19990719
			WO 2000-US16319	W 20000711
			US 2001-18037	A3 20011211

OTHER SOURCE(S): MARPAT 134:116236

GI



AB Indole derivs. I (R1 = (un)substituted alkyl, haloalkyl, alkenyl, alkynyl, carbonyl, or heterocyclyl connected directly or via a divalent linking group to the indole ring; R2 is H or a group containing 1-4 non-hydrogen atoms


plus any required hydrogen atoms; R3 is -L3-Z, where L3 is a bond, CH2, O, S, NH, or CO and Z is -C(=NO)C(=X)NH2, -C(=X)CONH2, or CRa2C(=X)NH2 (X = O or S and Ra = alkyl, aryl, alkaryl, alkoxy, aralkyl, CN); R4 is the group -(Lc)-(acylamino acid group), where Lc is an acylamino acid linker;

L7 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 R5 is H, a non-interfering substituent, or the group -(aa)-(acidic group), where aa is an acid linker; R6, R7 = H, a non-interfering substituent or (un)substituted carbonyl were prep'd. for inhibiting sPLA2 mediated release of fatty acids for treatment of inflammatory diseases such as septic shock. Thus, treatment of N-tert butoxycarbonyl-3-methoxy-2-methylaniline with N-methoxy-N-methylpropanamide and then trifluoroacetic acid afforded 2-ethyl-4-methoxy-1H-indole. N-benzylation, O-demethylation, alkylation with Me bromoacetate, reaction with oxalyl chloride and ammonia gave [[3-(aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetic acid Me ester (1). Reaction of 1 with glycine Me ester hydrochloride and sapon. afforded N-[[[3-(aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetyl]glycine (3a). Comps. 1 and 3a resp. showed IC50 = 49 and 71 nM for inhibition of human secreted PLA2.

IT 321153-17-7P 321153-19-9P 321153-21-3P
 321153-23-5P 321153-25-7P 321153-27-9P
 321153-29-1P 321153-31-5P 321153-33-7P
 321153-35-9P 321153-36-0P 321153-38-2P
 321153-40-6P 321153-42-8P 321153-44-0P
 321153-46-2P

RL: EAC (Biological activity or effector, except adverse); ESU (Biological study, unclassified); SYN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of indole amino acid derivs. as secretory phospholipase A2 (sPLA2) inhibitors)


RN 321153-17-7 CAPLUS
 CN Glycine, N-[[[3-(aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetyl]- (9CI) (CA INDEX NAME)




RN 321153-19-9 CAPLUS
 CN L-Alanine, N-[[[3-(aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 Absolute stereochemistry.




RN 321153-27-9 CAPLUS
 CN Propanedioic acid, [[[[3-(aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetyl]amino]- (9CI) (CA INDEX NAME)



RN 321153-29-1 CAPLUS
 CN L-Valine, N-[[[3-(aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 321153-31-5 CAPLUS
 CN L-Isoleucine, N-[[[3-(aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 321153-21-3 CAPLUS
 CN L-Leucine, N-[[[3-(aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 321153-23-5 CAPLUS
 CN L-Aspartic acid, N-[[[3-(aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 321153-25-7 CAPLUS
 CN L-Phenylalanine, N-[[[3-(aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 321153-33-7 CAPLUS
 CN Glycine, N-[[[3-(aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 321153-35-9 CAPLUS
 CN L-Alanine, N-[[[3-(aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 321153-36-0 CAPLUS
 CN L-Leucine, N-[[[3-(aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 321153-38-2 CAPLUS
 CN L-Aspartic acid, N-[[[3-(aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetyl]-, dimethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 321153-40-6 CAPLUS
 CN L-Phenylalanine, N-[[[3-(aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 321153-42-8 CAPLUS
 CN Propanedinic acid, [[[[3-(aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetyl]-, methyl ester (9CI) (CA INDEX NAME)

L7 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 indol-4-yl]oxy]acetyl]-, dimethyl ester (9CI) (CA INDEX NAME)




RN 321153-44-0 CAPLUS
 CN L-Valine, N-[[[3-(aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 321153-46-2 CAPLUS
 CN L-Isoleucine, N-[[[3-(aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


L7 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2000:441704 CAPLUS
 DOCUMENT NUMBER: 133:79346
 TITLE: Preparation of indoles as secretory phospholipase A2 inhibitors as anti-inflammatory agents
 INVENTOR(S): Bach, Nicholas James; Harper, Richard Waltz; Kinnick, Michael Dean; Lin, Ho-Shen; Morin, John Michael, Jr.; Richett, Michael Enrico
 PATENT ASSIGNEE(S): Eli Lilly and Company, USA
 SOURCE: FCT Int. Appl., 86 pp.
 CODEN: PIXXU2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000037358	A1	20000629	WO 1999-US30405	19991220
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CK, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, GR, GU, HD, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2356159	AA	20000629	CA 1999-2356159	19991220
EP 1144305	A1	20011017	EP 1999-967465	19991220
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
JP 2002532571	T2	20021002	JF 2000-589439	19991220
US 6391908	B1	20020521	US 2001-856942	20010530
PRIORITY APPLN. INFO.:			US 1998-113303P	P 19981222
			WO 1999-US30405	W 19991220

OTHER SOURCE(S): MARPAT 133:79346
 AB Indole derivs. are disclosed together with the use of such compds. for inhibiting human nonpancreatic secretory phospholipase A2 (sPLA2)-mediated release of fatty acids for treatment of inflammatory diseases such as septic shock. Thus, 2-[[[3-[[[2-(Aminooxo)-1-(N-hydroxyimino)]ethyl]-2-ethyl-(phenylmethyl)-1H-indol-4-yl]oxy]acetyl]-1H-indol-4-yl]oxy]acetic acid (I) was prepared by the hydrolysis of the corresponding ester with LiOH solution in THF. Thus, tablets contained 1250, microcryst. cellulose 400, fumed silica 10 and stearic acid 5 mg/tablet.
 IT 278601-74-4P 278601-75-5P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, Unclassified); SPN (Synthetic preparation); THU (Therapeutic use); RIO (Biological study); PREP (Preparation); USES (Uses)
 (preparation of indoles as secretory phospholipase A2 inhibitors as anti-inflammatory agents)
 RN 278601-74-4 CAPLUS
 CN 1H-indole-3-acetamide, 4-(2-amino-2-oxoethoxy)-2-ethyl-α-(methoxyimino)-1-(phenylmethyl)- (9CI) (CA INDEX NAME)

I7 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 278601-75-5 CAPLUS
 CN Glycine, N-[[[3-[2-amino-1-(methoxyimino)-2-oxoethyl]-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetyl]- (9CI) (CA INDEX NAME)



IT 278601-76-6P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of indoles as secretory phospholipase A2 inhibitors as anti-inflammatory agents)

RN 278601-76-6 CAPLUS
 CN Glycine, N-[[[3-[2-amino-1-(methoxyimino)-2-oxoethyl]-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetyl]-, methyl ester (9CI) (CA INDEX NAME)




REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2000:116896 CAPLUS
 DOCUMENT NUMBER: 132:151679
 TITLE: Preparation of indole sPLA2 inhibitors
 INVENTOR(S): Mihelich, Edward David; Phillips, Michael Leroy; Warshawsky, Alan M.
 PATENT ASSIGNEE(S): Eli Lilly and Company, USA
 SOURCE: PCT Int. Appl., 70 pp.
 CODEN: FIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000007591	A1	20000217	WO 1999-US17460	19990802
W:	AE, AL, AM, AT, AU, AZ, BA, BE, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GE, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, EF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2338727	AA	20000217	CA 1999-2338727	19990802
AU 9953314	A1	20000228	AU 1999-53314	19990802
EP 1100493	A1	20010523	EP 1999-938937	19990802
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
JP 2002522386	T2	20020723	JP 2000-563276	19990802
US 6608099	E1	20030619	US 2001-762070	20010130
US 2003191175	A1	20031009	US 2003-395657	20030321
PRIORITY APPL. INFO.:			US 1998-95109P	P 19980803
			WO 1999-US17460	W 19990802
			US 2001-762070	A3 20010130

OTHER SOURCE(S): MARPAT 132:151679
 GI




AB The title compds. [I; R1 = alkyl, haloalkyl, alkenyl, etc.; R2 = H, a


L7 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 group contg. 1-4 non-hydrogen atoms; R3 = L3-Z (wherein L3 = CH2, O, S, NH, CO; Z = acetamide, thioacetamide, glyoxylamide, etc.); R4, R5 = H, non-interfering substituent, La-acylsulfonamide (La = a divalent linker having a linker length of 1-8; provided that at least one of R4 and R5 must be La-acylsulfonamide); R6, R7 = H, cycloalkyl, heterocyclyl, etc.), useful for inhibiting sPLA2 mediated release of fatty acids for treatment of inflammatory diseases such as septic shock, were prepd. and formulated. Thus, reacting 1-benzyl-2-ethyl-4-carboxymethoxy-indole-3-glyoxylamide (prepn. given) with methanesulfonamide in the presence of 4-dimethylaminopyridine and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride in CH2Cl2 afforded 19% II which showed IC50 of 12 nM against human secreted PLA2.

IT 258262-49-6P 258262-50-9P 258262-51-0P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of indole sPLA2 inhibitors)

RN 258262-49-6 CAPLUS
 CN 1H-Indole-3-acetamide, 2-ethyl-4-[2-[(methylsulfonyl)amino]-2-oxoethoxy]-α-oxo-1-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 258262-50-9 CAPLUS
 CN 1H-Indole-3-acetamide, 2-ethyl-α-oxo-4-[2-oxo-2-[(phenylsulfonyl)amino]ethoxy]-1-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 258262-51-0 CAPLUS
 CN 1H-Indole-3-acetamide, 2-ethyl-α-oxo-4-[2-oxo-2-[[[2-(trifluoromethyl)sulfonyl]amino]ethoxy]-1-(phenylmethyl)- (9CI) (CA INDEX NAME)

L7 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 258262-52-1 CAPLUS
 CN 1H-Indole-3-acetamide, 2-ethyl-4-[2-[[[2-(methylphenyl)sulfonyl]amino]-2-oxoethoxy]-α-oxo-1-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 258262-53-2 CAPLUS
 CN 1H-Indole-3-acetamide, 4-[2-[[[4-(2-aminoethyl)phenyl]sulfonyl]amino]-2-oxoethoxy]-2-ethyl-α-oxo-1-(phenylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)


L7 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)



IT 258262-55-4P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of indole sPLA2 inhibitors)
 RN 258262-55-4 CAPLUS
 CN Carbanic acid, [2-{4-[[[3-(aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetyl]amino]sulfonylphenyl]ethyl]-, 1,1-dimethylethyl ester (SCI) (CA INDEX NAME)

L7 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)

PAGE 1-A



PAGE 2-A

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L7 ANSWER 14 OF 16 CAPLUS COPYRIGHT 2004 ACS ON STN

ACCESSION NUMBER: 1996:713060 CAPLUS
 DOCUMENT NUMBER: 126:69724
 TITLE: Indole Inhibitors of Human Nonpancreatic Secretory Phospholipase A2. 3. Indole-3-glyoxamides
 Draheim, Susan E.; Bach, Nicholas J.; Dillard, Robert D.; Berry, Dennis R.; Carlson, Donald G.; Chirgadze, Nickolay Y.; Clawson, David K.; Hartley, Lawrence W.; Johnson, Lea M.; et al.
 CORPORATE SOURCE: Lilly Corporate Center, Eli Lilly and Company, Indianapolis, IN, 46285, USA
 SOURCE: Journal of Medicinal Chemistry (1996), 39(26), 5159-5175
 CODEN: JMCMAR; ISSN: 0022-2623
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB The preceding papers of this series detail the development of functionalized indole-3-acetamides as inhibitors of hnpa-PLA2. We describe here the extension of the structure-activity relationship to include a series of indole-3-glyoxamide derivs. Functionalized indole-3-glyoxamides with an acidic substituent appended to the 4- or 5-position of the indole ring were prepared and tested as inhibitors of hnpa-PLA2. It was found that the indole-3-glyoxamides with a 4-oxoacetic acid substituent had optimal inhibitory activity. These inhibitors exhibited an improvement in potency over the best of the indole-3-acetamides, and LY315920 (6m) was selected for evaluation clin. as an hnpa-PLA2 inhibitor.

IT 165298-58-2P
 RL: RAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation and SAR of indoleglyoxamides as inhibitors of human nonpancreatic secretory phospholipase A2)

RN 165298-58-2 CAPLUS
 CN 1H-Indole-3-acetamide, 4-(2-amino-2-oxoethoxy)-2-ethyl-1-(phenylmethyl)- (SCI) (CA INDEX NAME)




L7 ANSWER 15 OF 16 CAPLUS COPYRIGHT 2004 ACS ON STN

ACCESSION NUMBER: 1996:713059 CAPLUS
 DOCUMENT NUMBER: 126:84068
 TITLE: Indole Inhibitors of Human Nonpancreatic Secretory Phospholipase A2. 2. Indole-3-acetamides with Additional Functionality
 Dillard, Robert D.; Bach, Nicholas J.; Draheim, Susan E.; Berry, Dennis R.; Carlson, Donald G.; Chirgadze, Nickolay Y.; Clawson, David K.; Hartley, Lawrence W.; Johnson, Lea M.; et al.
 CORPORATE SOURCE: Lilly Corporate Center, Eli Lilly and Company, Indianapolis, IN, 46285, USA
 SOURCE: Journal of Medicinal Chemistry (1996), 39(26), 5137-5158
 CODEN: JMCMAR; ISSN: 0022-2623
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB As reported in our previous paper, a series of indole-3-acetamides which possessed potency and selectivity as inhibitors of human nonpancreatic secretory phospholipase A2 (hnpa-PLA2) was developed. The design of these compds. was based on information derived from x-ray crystal structures determined for complexes between the enzyme and its inhibitors. We describe here the further implementation of this structure-based design strategy and continued SAR development to produce indole-3-acetamides with addnl. functionalities which provide increased interaction with important residues within the enzyme active site. These efforts led to inhibitors with substantially enhanced potency and selectivity.

IT 164083-87-8P
 RL: RAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and SAR of indoleacetamides as inhibitors of human nonpancreatic secretory phospholipase A2)


RN 164083-87-8 CAPLUS
 CN Acetic acid, [[3-(2-amino-2-oxoethyl)-2-methyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-, hydrazide (SCI) (CA INDEX NAME)



IT 164083-88-9P
 RL: RAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation and SAR of indoleacetamides as inhibitors of human nonpancreatic secretory phospholipase A2)

RN 164083-88-9 CAPLUS
 CN 1H-Indole-3-acetamide, 4-(2-amino-2-oxoethoxy)-2-methyl-1-(phenylmethyl)- (SCI) (CA INDEX NAME)

L7 ANSWER 15 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



L7 ANSWER 16 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1995:621499 CAPLUS

DOCUMENT NUMBER: 123:32954

TITLE: Preparation of 1H-indole-3-acetamides as sPLA2 inhibitors.

INVENTOR(S): Bach, Nicholas James; Dillard, Robert Delane; Draheim, Susan Elizabeth; Hermann, Robert Fell; Schevitz, Richard Walter

PATENT ASSIGNEE(S): Eli Lilly and Co., USA

SOURCE: Eur. Pat. Appl., 123 pp.

CODEN: EFXDLW

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 620215	A1	19941019	EP 1994-302666	19940414
EP 620215	B1	19990818		
R: AT, BE, CH, DE, DK, ES, FR, GE, GR, IE, IT, LI, LU, NL, PT, SE				
HU 70836	A2	19951128	HU 1994-1060	19940413
CA 2121323	AA	19941017	CA 1994-2121323	19940414
BR 9401482	A	19941018	BR 1994-1482	19940414
AT 183503	F	19990915	AT 1994-302666	19940414
ES 2138648	T3	20000116	ES 1994-302666	19940414
CZ 289750	R6	20020313	CZ 1994-893	19940414
FI 9401767	A	19941017	FI 1994-1767	19940415
NO 9401361	A	19941017	NO 1994-1361	19940415
AU 9459492	A1	19941020	AU 1994-59492	19940415
AU 676884	E2	19970327		
JP 07025850	A2	19950127	JP 1994-77650	19940415
CN 1098715	A	19950215	CN 1994-104434	19940415
CN 1068588	S	20010718		
ZA 9402615	A	19951016	ZA 1994-2615	19940415
RU 2162463	C2	20010127	RU 1994-12930	19940415
PL 181319	B1	20010731	PL 1994-303028	19940415
US 5684034	A	19971104	US 1996-435256	19950505
US 6252084	E1	20010626	US 1997-962603	19971031
GR 3031783	T3	20000229	GR 1999-402875	19991108
PRIORITY APPLN. INFO.:				
			US 1997-48629	A 19930416
			US 1994-208721	A 19940315
			US 1995-435256	A1 19950505
OTHER SOURCE(S): MARPAT 123:32954				
GI				


L7 ANSWER 16 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




AB Title compds. [I: R1 = (cyclo)alkyl, alkenyl, aryl, alkylamino, etc.; R2 = H, halo, alkyl, alkoxy, etc.; R3 = H, halo, Me; R4-R7 = H, (cyclo)alkyl, aryl(alkyl), alkoxy, etc.; X = O or S] were prepared. Thus, 1-(2-tert-butoxycarbonylamino-5-methoxyphenyl)-2-butanone (preparation from 4-methoxy-2-methylaniline given) was cyclized and the product alkylated by BrCH2CO3Me to give, in 4 addnl. steps, I (R1 = CH2Ph, R2 = Et, R3 = R4 = R6 = R7 = H, R5 = OR, X = O) (II: R = H) which was condensed with Br(CH2)3P(O)(OMe)2 to give, after saponification, II (R = (CH2)3P(O)(OH)2).

The latter had IC50 of 0.03μM against human sPLA2 in vitro.

IT 164083-87-8P 164083-88-9P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); RIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of 1H-indole-3-acetamides as sPLA2 inhibitors.)
 RN 164083-87-8 CAPLUS
 CN Acetic acid, [[3-(2-amino-2-oxoethyl)-2-methyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-, hydrazide (9CI) (CA INDEX NAME)



RN 164083-88-9 CAPLUS
 CN 1H-Indole-3-acetamide, 4-(2-amino-2-oxoethyl)-2-methyl-1-(phenylmethyl)- (9CI) (CA INDEX NAME)



L7 ANSWER 16 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

=> fil reg

COST IN U.S. DOLLARS

SINCE FILE ENTRY	TOTAL SESSION
77.42	274.97

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE ENTRY	TOTAL SESSION
-11.09	-11.09

CA SUBSCRIBER PRICE

FILE 'REGISTRY' ENTERED AT 08:33:30 ON 22 MAY 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 20 MAY 2004 HIGHEST RN 684211-73-2
DICTIONARY FILE UPDATES: 20 MAY 2004 HIGHEST RN 684211-73-2

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004


Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=>

Uploading C:\STNEXP4\QUERIES\10629992c.str



chain nodes :


10 11 12 13 14 16 17 20 21 22 23 24

ring nodes :
1 2 3 4 5 6 7 8 9
chain bonds :
7-10 9-16 10-11 11-12 11-13 14-20 16-17 20-21 21-22 21-23 22-24
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9
exact/norm bonds :
5-7 6-9 7-8 8-9 9-16 11-12 11-13 14-20 21-22 21-23 22-24
exact bonds :
7-10 10-11 16-17 20-21
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:Atom 20:CLASS
21:CLASS 22:CLASS 23:CLASS 24:CLASS

L8 STRUCTURE UPLOADED

=> d
L8 HAS NO ANSWERS
L8 STR



Structure attributes must be viewed using STN Express query preparation.

=> d his

(FILE 'HOME' ENTERED AT 08:29:27 ON 22 MAY 2004)

FILE 'REGISTRY' ENTERED AT 08:29:51 ON 22 MAY 2004

L1 STRUCTURE UPLOADED
 L2 46 S L1
 L3 1067 S L1 FULL
 L4 STRUCTURE UPLOADED
 L5 62 S L4 FULL SUB=L3
 L6 62 S L5 AND CAPLUS/LC

FILE 'CAPLUS' ENTERED AT 08:31:32 ON 22 MAY 2004

L7 16 S L6

FILE 'REGISTRY' ENTERED AT 08:33:30 ON 22 MAY 2004

L8 STRUCTURE UPLOADED

=> s 18 subset-15 full

COMBINATION OF STRUCTURE AND TEXT TERMS NOT VALID

The query entered contains both search terms created by structure-building or screen commands and text search terms. L#s created via the STRUCTURE or SCREEN commands must be searched in the structures files separately from text terms or profiles. The L# answer sets from structure searches can be used in crossover searches and can be combined with text terms.

=> s 18 subset=15 full

FULL SUBSET SEARCH INITIATED 08:34:47 FILE 'REGISTRY'

FULL SUBSET SCREEN SEARCH COMPLETED - 37 TO ITERATE

100.0% PROCESSED 37 ITERATIONS

6 ANSWERS

SEARCH TIME: 00.00.01

L9 6 SEA SUB=L5 SSS FUL L8

=> fil caplus

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
37.49	312.46

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
0.00	-11.09

CA SUBSCRIBER PRICE

FILE 'CAPLUS' ENTERED AT 08:34:52 ON 22 MAY 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is

strictly prohibited.

FILE COVERS 1907 - 22 May 2004 VOL 140 ISS 22
FILE LAST UPDATED: 21 May 2004 (20040521/ED)

This file contains CAS Registry Numbers for easy and accurate
substance identification.


=> s l9

L10 1 L9

=> d ibib abs hitstr

L10 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2001:228857 CAPLUS
 DOCUMENT NUMBER: 134:252258
 TITLE: Preparation of indole derivatives as human non-pancreatic secretory phospholipase A2 (sPLA2) inhibitors
 INVENTOR(S): Harper, Richard Waltz; Lin, Ho-Shan; Richett, Michael Enrico
 PATENT ASSIGNEE(S): Eli Lilly and Company, USA
 SOURCE: PCT Int. Appl., 117 pp.
 CODEN: PIXXD2
 Patent
 DOCUMENT TYPE: English
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001021587	A2	20010329	WO 2000-US20816	20000907
WO 2001021587	A3	20011011		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BE, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, FR, GB, GR, GU, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CH, GA, GN, GW, ML, MR, NE, SN, TD, TG			
EP 1220839	A2	20020710	EP 2000-959170	20000907
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, FT, IE, SI, LT, LV, FI, RO, MK, CY, AL			
JP 2003509491	T2	20030311	JP 2001-524967	20000907
US 2004029948	A1	20040212	US 2003-629992	20030730
PRIORITY APPLN. INFO.:			US 1999-154836P	F 19990920
			WO 2000-US20816	W 20000907
			US 2002-69824	A3 20020221
OTHER SOURCE(S):		MAREPAT 134:252258		
GI				



AR A class of novel indole represented by formula [I]; R1 is selected from groups (a), (b), and (c) wherein: (a) is C7-20 alkyl, C7-20 haloalkyl, C7-20 alkenyl, C7-20 alkynyl, carbocyclic radical, or heterocyclic radical, or (b) is a member of (a) substituted with one or more independently selected non-interfering substituents; or (c) is (a) or (b)


L10 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 group linked to a divalent linking group of 1 to 8 atoms; R2 is hydrogen, or a group contg. 1 to 4 nonhydrogen atoms plus any required hydrogen atoms; R3 is -(L3)-Z, where (L3) is a divalent linker group selected from a bond or a divalent group selected from: CH2, O, S, NH, CO and Z is selected from a group represented by the formulas, C(:NORa)C(:X)NH2, C(:X)CONH2, C(Ra)2C(:X)NH2 or wherein, X is oxygen or sulfur; and Ra is selected from hydrogen, C1-8 alkyl, aryl, C1-8 alkaryl, C1-9 alkoxy, aralkyl and cyano; R4 is the group, -(L4) (hydroxyfunctional amide); wherein (L4), is an hydroxyfunctional amide linker having an hydroxyfunctional amide linker length of 1 to 8; R5 is selected from hydrogen, a non-interfering substituent, or the group, -(La)-(acidic group); wherein -(La)-, is an acid linker having an acid linker length of 1 to 8; R6 and R7 are selected from hydrogen, non-interfering substituent, carbocyclic radical, carbocyclic radical substituted with non-interfering substituent(s), heterocyclic radicals, and heterocyclic radical substituted with non-interfering substituent(s) is prepd. These compds. inhibit sPLA2-mediated release of fatty acids for treatment of inflammatory diseases such as septic shock. Thus, [[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetic acid Me ester was condensed with O-phenylhydroxylamine hydrochloride in the presence of collidine and benzo[1,2,3-cd:4,5-b']diazole-1-yloxytris-(dimethylamino)phosphonium hexafluorophosphate in DMF at ambient temp. for 2 h to give 2-[[3-(aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-N-(phenyloxy)acetamide (II). II in vitro showed IC50 of 9.012.0 nM against sPLA2.

IT 331440-80-3P 331440-86-9P 331440-92-7P
 331441-07-7P 331441-09-9P 331441-15-7P
 RI: FAC (Biological activity or effector, except adverse); FSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BTOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of indole derivs. as human non-pancreatic secretory phospholipase A2 (sPLA2) inhibitors and inhibitors of sPLA2-mediated release of fatty acids for treatment of inflammatory diseases such as septic shock)
 RN 331440-80-3 CAPLUS
 CN 1H-Indole-3-acetamide, 2-ethyl-4-[2-(hydroxyamino)-2-oxoethoxy]-α-oxo-1-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 331440-86-9 CAPLUS
 CN 1H-Indole-3-acetamide, 2-ethyl-4-[2-(hydroxymethylamino)-2-oxoethoxy]-α-oxo-1-(phenylmethyl)- (9CI) (CA INDEX NAME)


L10 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 331440-92-7 CAPLUS
 CN 1H-Indole-3-acetamide, 2-ethyl-4-[2-(hydroxy-2-propenylamino)-2-oxoethoxy]-α-oxo-1-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 331441-07-7 CAPLUS
 CN 1H-Indole-3-acetamide, 4-[2-(cyclohexylhydroxyamino)-2-oxoethoxy]-2-ethyl-α-oxo-1-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 331441-09-9 CAPLUS
 CN 1H-Indole-3-acetamide, 2-ethyl-4-[2-(hydroxyamino)-2-oxoethoxy]-1-(phenylmethyl)- (9CI) (CA INDEX NAME)

L10 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 331441-15-7 CAPLUS
 CN 1H-Indole-3-acetamide, 2-ethyl-4-[2-(hydroxy(phenylmethyl)amino)-2-oxoethoxy]-α-oxo-1-(phenylmethyl)- (9CI) (CA INDEX NAME)



=> log y

COST IN U.S. DOLLARS

SINCE FILE
ENTRY

TOTAL
SESSION

FULL ESTIMATED COST

6.95

319.41

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE
ENTRY

TOTAL
SESSION

CA SUBSCRIBER PRICE

-0.69

-11.78

STN INTERNATIONAL LOGOFF AT 08:38:04 ON 22 MAY 2004